VEGAS-all |
Neurotrophin signaling pathway (hsa04722) |
116 |
10 |
6.96 × 10-5
|
0.007 |
Adipocytokine signaling pathway (hsa04920) |
55 |
6 |
6.34 × 10-4
|
0.065 |
Cell cycle (hsa04110) |
114 |
8 |
1.56 × 10-3
|
0.158 |
Chronic myeloid leukemia (hsa05220) |
70 |
6 |
2.28 × 10-3
|
0.227 |
Vasopressin-regulated water reabsorption (hsa04962) |
34 |
4 |
4.10 × 10-3
|
0.405 |
|
|
|
|
|
VEGAS-top |
Cell cycle (hsa04110) |
114 |
20 |
8.61 × 10-8
|
1.15 × 10-5
|
Neurotrophin signaling pathway (hsa04722) |
116 |
17 |
1.14 × 10-5
|
1.51 × 10-3
|
Endometrial cancer (hsa05213) |
49 |
8 |
1.31 × 10-3
|
0.173 |
RIG-I-like receptor signaling pathway (hsa04622) |
50 |
8 |
1.50 × 10-3
|
0.196 |
Chronic myeloid leukemia (hsa05220) |
70 |
9 |
3.69 × 10-3
|
0.479 |
|
|
|
|
|
minP |
T cell receptor signaling pathway (hsa04660) |
104 |
17 |
2.68 × 10-6
|
3.43 × 10-4
|
Neurotrophin signaling pathway (hsa04722) |
116 |
18 |
2.91 × 10-6
|
3.69 × 10-4
|
Antigen processing and presentation (hsa04612) |
59 |
12 |
8.58 × 10-6
|
1.08 × 10-3
|
Chronic myeloid leukemia (hsa05220) |
70 |
13 |
1.03 × 10-5
|
1.28 × 10-3
|
Non-small cell lung cancer (hsa05223) |
51 |
11 |
1.14 × 10-5
|
1.42 × 10-3
|